JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Затворен

3.27 -0.3

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.27

Максимум

3.28

Ключови измерители
By Trading Economics
Приходи	-12M -25M
Продажби	190K 1.8M
Марж на печалбата	-1,390.363
Служители	44
EBITDA	-12M -24M

Дивиденти
By Dow Jones
Следващи печалби	7.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	158K 642M
Предишно отваряне	3.57
Предишно затваряне	3.27

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.08.2025 г., 17:41 ч. UTC

Печалби

Значими двигатели на пазара

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

1.08.2025 г., 17:40 ч. UTC

Печалби

Значими двигатели на пазара

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

2.08.2025 г., 15:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- Update

2.08.2025 г., 13:29 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2.08.2025 г., 13:10 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2.08.2025 г., 12:59 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2.08.2025 г., 12:53 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2.08.2025 г., 12:52 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2.08.2025 г., 12:44 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2.08.2025 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.08.2025 г., 22:31 ч. UTC

Печалби

MicroStrategy Stock Drops 9%. New Equity Guidelines Could Be the Reason. -- Barrons.com

1.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.08.2025 г., 20:28 ч. UTC

Придобивния, сливания и поглъщания

EOG Resources Completes $5.6B Purchase of Encino Acquisition Partners

1.08.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

1.08.2025 г., 20:08 ч. UTC

Пазарно говорене

U.S. Stocks Tumble as U.S. Jobs Market Weakens, New Tariffs Hit -- Market Talk

1.08.2025 г., 19:54 ч. UTC

Пазарно говорене

Mexico Manufacturing Indexes Mixed in July -- Market Talk

1.08.2025 г., 19:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.08.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Start Month With Jobs-Driven Decline -- Market Talk

1.08.2025 г., 19:40 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

1.08.2025 г., 19:40 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Above Key Support -- Market Talk

1.08.2025 г., 19:19 ч. UTC

Пазарно говорене

Livestock Brings Positive Momentum Into August -- Market Talk

1.08.2025 г., 19:13 ч. UTC

Пазарно говорене

Crude Falls on Soft U.S. Jobs Data, OPEC+ Output Expectations -- Market Talk

1.08.2025 г., 19:07 ч. UTC

Придобивния, сливания и поглъщания

Danone to Explore Buying Lifeway Foods. The Third Time Could Be Different. -- Barrons.com

1.08.2025 г., 18:38 ч. UTC

Пазарно говорене

Grains Shrug Off Lower Dollar -- Market Talk

1.08.2025 г., 18:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.08.2025 г., 17:53 ч. UTC

Придобивния, сливания и поглъщания

Correction to M&A Is Back. These Stocks Could Be Targets. -- Barrons.com

1.08.2025 г., 17:52 ч. UTC

Пазарно говорене

Gold Finishes Higher Amid Weak July Hiring and Tariffs -- Market Talk

1.08.2025 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down By 5 to 410 -- Market Talk

1.08.2025 г., 17:06 ч. UTC

Печалби

Earnings Season Is Going Really Well. Don't Overthink It. -- Barrons.com

1.08.2025 г., 16:55 ч. UTC

Печалби

Big Takeaways From Big Tech Earnings -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.